FDA Blocks Much-Anticipated BioMarin Hemophilia Gene Therapy
Regulation
FDA Blocks Much-Anticipated BioMarin Hemophilia Gene Therapy

FAIRLESS HILLS, PA (AP) — Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a... Read More

Straight From The Well
scroll top